Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 09:10:25 17/07/2024 pm IST			5-day change	1st Jan Change
26.68 ^EUR	+2.40%		+2.12%	-20.67%

17/07	Global markets live: Adidas, TSMC, Vale, HSBC, J&J...
17/07	Bayer: successful trial in prostate cancer	CF

BAYER AG : Bernstein maintains a Buy rating

January 04, 2021 at 05:29 pm IST

Bernstein analyst Wimal Kapadia maintains his Buy rating on the stock. The target price continues to be set at EUR 74.

Latest news about Bayer AG

Global markets live: Adidas, TSMC, Vale, HSBC, J&J...	17/07
Bayer: successful trial in prostate cancer	17/07	CF
BAYER AG : JP Morgan remains Neutral	17/07	ZD
Bayer: new positive data for Nubeqa	17/07	CF
Bayer with trial success in prostate cancer - Analyst: As expected	17/07	DP
BAYER AG : Goldman Sachs sticks Neutral	17/07	ZD
Bayer's Prostate Cancer Combo Extends Progression-Free Survival in Late-stage Trial	17/07	MT
Bayer's Nubeqa Meets Key Goal in Late-Stage Prostate Cancer Trial	17/07	DJ
Bayer eyes wider Nubeqa use on new prostate cancer trial data	17/07	RE
Bayer seeks approval extension for cancer drug Nubeqa following positive data	17/07	RE
Bayer with trial success in prostate cancer - Larger patient group responsive	17/07	DP
Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint	17/07	CI
ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC	17/07	CI
BAYER AG : UBS sticks Neutral	15/07	ZD
European companies cut jobs as economy sputters	15/07	RE
European Midday Briefing : Stocks Extend Rally as U.S. Rate Cut Hopes Deepen	12/07	DJ
BAYER AG : Jefferies gives a Neutral rating	12/07	ZD
Cooling Inflation in Germany, US Boosts DAX Index	11/07	MT
Bayer: FDA Fast Track designation for Parkinson's treatment	11/07	CF
Bayer's Gene Therapy for Parkinson's Gets US Fast Track, UK Innovation Passport Designations	11/07	MT
Fast-track status for gene therapy boosts Bayer	11/07	DP
BASF announces planned closure of two weed killer sites in Germany	10/07	RE
BAYER AG : JP Morgan reaffirms its Neutral rating	10/07	ZD
European companies cut jobs as economy sputters	09/07	RE
BAYER AG : Gets a Neutral rating from Deutsche Bank	09/07	ZD

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release

Related indices

Euro STOXX 50 Index , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : As soft as anticipated

May 14, 2024 at 11:42 pm IST

Bayer AG: Not out of the woods yet

March 06, 2024 at 09:16 pm IST

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

26.68 EUR

Average target price

35.91 EUR

Spread / Average Target

+34.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-20.67%	27.86B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

BAYER AG : Bernstein maintains a Buy rating

Latest news about Bayer AG

Chart Bayer AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bayer AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals